Cancer vaccines are designed to effectively induce cancer antigen‐specific cytotoxic T lymphocytes and enhance immune response.37, 47 K.Mimura et al performed phase I and II clinical trials of cancer vaccine using three human leukocyte antigen‐A24 (HLA‐A24)‐binding peptides from TTK protein kinase (TTK), lymphocyte antigen‐6 complex locus K (LY6K), and insulin‐like growth factor‐II mRNA binding protein‐3 (IMP3). This evidence concerns the gene LY6K and cancer.